AB0529 GLUCOCORTICOIDS WITHDRAWN IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT STATE: A DESIRABLE GOAL

Background Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels serologic markers without activity. The outcome and treatment strategy after SACQ achievement remains unclear. After achieving the goal, maintaining low-dose glucocorticoids has always been both blessing curse [1,2] . Whether discontinuation desirable goal in patients achieved was controversial. Objectives In this multi-center prospective study, we aimed to identify risk flares, organ damage accumulation, feasibility SLE who as SACQ. Methods This observational study conducted based on data from Chinese research (CSTAR) registry. Demographic characteristics, autoantibody profiles, manifestations, disease activity status, damage, profile were collected at recruitment during follow-up. defined least 6-months period with persistent (positive anti-dsDNA antibody, and/or hypocomplementemia), (SQCQ) or flare measured according SELENA-SLEDAI index (SFI). Organ principally assessed using SLICC (SDI). Results Of 4107 patients, 1889 reached stage (990 SACQ, 899 SQCQ). Among 990 364 (36.7%) underwent 163(16.5%) showed 47 (4.7%) developed renal 21 (2.1%) died mean follow-up 7.30 years. Compared SQCQ, higher flares (HR=1.47, 95% CI 1.25-1.73，p<0.001) accumulation (HR=2.02, 1.23-3.33, p=0.004). Furthermore, 224 (22.6%) withdraw 125 (55.8%) them did not Low-dose favorable factor long-term survival (HR=0.22, 85% CI, 0.05-0.96, P=0.044). As shown Figure 1, withdrawing can reduce (p=0.0075), especially (p=0.045), even experience discontinuation. (A) (B) 1. Cumulative probability new-onset maintain glucocorticoids, but successful glucocorticoids. Conclusion Our results suggest that withdrawal under tight survallance could be considered prevent accrual damage. References [1]Apostolopoulos D, et al. Lancet Rheumatology 2020;2(1):e24-e30. [2]Mathian A, Ann Rheum Dis 2020;79(3):339-46. Acknowledgements We thank CSTAR co-authors following for assistance cases collections. Disclosure Interests None Declared.